{"id":"low-dose-oral-anticoagulant","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding"},{"rate":null,"effect":"Gastrointestinal disturbance"}]},"_chembl":{"chemblId":"CHEMBL2108778","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"These agents work by inhibiting key factors in the coagulation cascade (such as Factor Xa or thrombin) at sub-therapeutic doses, providing anticoagulant activity sufficient to prevent pathological clotting while maintaining a favorable safety profile compared to standard-dose anticoagulation. The reduced dose strategy aims to balance efficacy in thromboprophylaxis or treatment with lower rates of major bleeding complications.","oneSentence":"Low-dose oral anticoagulants inhibit blood coagulation factors to reduce thrombus formation while minimizing bleeding risk through reduced dosing.","_ai_confidence":"low"},"_scrapedAt":"2026-03-27T23:53:19.561Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Thromboprophylaxis or anticoagulation (specific indication not detailed)"}]},"trialDetails":[{"nctId":"NCT03568890","phase":"PHASE4","title":"Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec","startDate":"2018-09-01","conditions":"Left Atrial Appendage Closure, Thrombosis, Stroke","enrollment":510},{"nctId":"NCT05198960","phase":"PHASE3","title":"AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms","status":"RECRUITING","sponsor":"University Hospital, Brest","startDate":"2022-07-13","conditions":"Polycythemia Vera, Essential Thrombocythemia, Prefibrotic/Early Primary Myelofibrosis","enrollment":1308},{"nctId":"NCT07454707","phase":"PHASE3","title":"Testing a New Treatment Strategy to Improve Secondary Stroke Prevention for Older Adults: The STROKE75+ Trial","status":"NOT_YET_RECRUITING","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2026-04","conditions":"Stroke, Ischemic","enrollment":1204},{"nctId":"NCT07432529","phase":"PHASE3","title":"Design and Rationale of the COLT Study","status":"NOT_YET_RECRUITING","sponsor":"Azienda Sanitaria Locale ASL 6, Livorno","startDate":"2026-06-01","conditions":"Venous Thrombosis Deep (Limbs), Post-thrombotic Syndrome, Venous Thromboembolism (VTE)","enrollment":940},{"nctId":"NCT03968393","phase":"PHASE4","title":"Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress","status":"RECRUITING","sponsor":"Population Health Research Institute","startDate":"2019-06-14","conditions":"Stroke, Atrial Fibrillation","enrollment":2270},{"nctId":"NCT07270263","phase":"NA","title":"Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies","status":"RECRUITING","sponsor":"Medical University of Gdansk","startDate":"2024-11-22","conditions":"Lymphoma, Leukemia, Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma","enrollment":100},{"nctId":"NCT06195540","phase":"PHASE3","title":"RIVAroxaban Versus Low-molecular Weight Heparin in Patients With Lower Limb Trauma Requiring Brace or CASTing","status":"RECRUITING","sponsor":"University Hospital, Angers","startDate":"2024-07-19","conditions":"Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism","enrollment":1424},{"nctId":"NCT03263117","phase":"PHASE4","title":"SEdation Versus General Anesthesia for Endovascular Therapy in Acute Ischemic Stroke","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2018-07-01","conditions":"Stroke","enrollment":260},{"nctId":"NCT07185295","phase":"PHASE4","title":"Short-term Interruption Versus Continuous Anticoagulation in Colorectal Polypectomy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Outcomes'10","startDate":"2024-10-18","conditions":"Anticoagulated Patients","enrollment":481},{"nctId":"NCT07228663","phase":"PHASE3","title":"Hip Fracture Surgery Arterial and Venous Thrombotic Events Prevention","status":"NOT_YET_RECRUITING","sponsor":"McMaster University","startDate":"2025-12-01","conditions":"Hip Fracture Surgery, Cardiovascular Prevention, Venous Thromboembolism (VTE)","enrollment":100},{"nctId":"NCT04867837","phase":"PHASE3","title":"Study of OCTAPLEX in Patients With Acute Major Bleeding on DOAC Therapy With Factor Xa Inhibitor","status":"RECRUITING","sponsor":"Octapharma","startDate":"2021-09-01","conditions":"Acute Major Bleeding","enrollment":260},{"nctId":"NCT04755283","phase":"PHASE2","title":"Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Anthos Therapeutics, Inc.","startDate":"2021-02-02","conditions":"Atrial Fibrillation (AF), Stroke","enrollment":1287},{"nctId":"NCT06517563","phase":"PHASE1","title":"Effects of VMX-C001 on the Anticoagulant Effect of Different Forms of Heparin","status":"ACTIVE_NOT_RECRUITING","sponsor":"VarmX B.V.","startDate":"2024-08-14","conditions":"Coagulation Disorder","enrollment":16},{"nctId":"NCT05990894","phase":"","title":"Steroid for Treatment of Acute/Subacute Severe Cerebral Venous Thrombosis.","status":"COMPLETED","sponsor":"Xuanwu Hospital, Beijing","startDate":"2020-07-01","conditions":"Cerebral Venous Thrombosis","enrollment":170},{"nctId":"NCT04700826","phase":"PHASE4","title":"Preventing Stroke, Premature Death and Cognitive Decline in a Broader Community of Patients With Atrial Fibrillation","status":"RECRUITING","sponsor":"University of Birmingham","startDate":"2021-06-01","conditions":"Atrial Fibrillation","enrollment":3000},{"nctId":"NCT06965244","phase":"PHASE3","title":"Lenalidomide vs Methotrexate in Difficult-to-treat Cutaneous Lupus Erythematosus","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2025-10-01","conditions":"Cutaneous Lupus Erythematosus (CLE)","enrollment":122},{"nctId":"NCT05735639","phase":"PHASE4","title":"THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE)","status":"RECRUITING","sponsor":"Imperial College London","startDate":"2024-01-22","conditions":"Venous Thromboembolism, Varicose Veins","enrollment":6660},{"nctId":"NCT02798471","phase":"PHASE3","title":"Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE)","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2017-03-27","conditions":"Venous Thromboembolism (VTE), Pulmonary Embolism, Deep Vein Thrombosis (DVT)","enrollment":290},{"nctId":"NCT06402851","phase":"PHASE4","title":"Vitamin K AntagonISt, Factor Xa Inhibitor or No Anticoagulation in Atrial Fibrillation and DIalytic End-stage Renal DiseasE (VISIONAIRE)","status":"RECRUITING","sponsor":"Hospital Sirio-Libanes","startDate":"2024-12-18","conditions":"Atrium; Fibrillation, Chronic Kidney Diseases","enrollment":1500},{"nctId":"NCT02618577","phase":"PHASE3","title":"Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate Episodes","status":"TERMINATED","sponsor":"Atrial Fibrillation Network","startDate":"2016-02","conditions":"Atrial High Rate Episodes","enrollment":2608},{"nctId":"NCT06352632","phase":"PHASE3","title":"ACT-GLOBAL Adaptive Platform Trial for Stroke","status":"RECRUITING","sponsor":"The George Institute","startDate":"2024-09-26","conditions":"Stroke","enrollment":20000},{"nctId":"NCT04508855","phase":"","title":"Management of Atrial Fibrillation in Patients With Cancer (MAFIC Study)","status":"WITHDRAWN","sponsor":"AHEPA University Hospital","startDate":"2020-08-01","conditions":"Cancer, Atrial Fibrillation","enrollment":""},{"nctId":"NCT06487052","phase":"NA","title":"Evaluation of the Standard Catheter-directed Thrombolysis Effectiveness in Intermediate-High-Risk Pulmonary Embolism Patients","status":"RECRUITING","sponsor":"Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health","startDate":"2024-01-10","conditions":"Pulmonary Embolism Acute","enrollment":100},{"nctId":"NCT06476301","phase":"PHASE4","title":"Efficacy and Safety of Rivaroxaban in the Early Postoperative Period for Patients With Bioprosthetic Valves","status":"NOT_YET_RECRUITING","sponsor":"RenJi Hospital","startDate":"2024-08-01","conditions":"Anticoagulation","enrollment":250},{"nctId":"NCT04164693","phase":"NA","title":"Efficacy and Safety of Short-term Postoperative Anticoagulant Therapy to Prevente Thrombosis in Arterovenous Fistula","status":"COMPLETED","sponsor":"First Affiliated Hospital of Chongqing Medical University","startDate":"2019-01-01","conditions":"Thrombosis","enrollment":287},{"nctId":"NCT04066764","phase":"PHASE3","title":"Rivaroxaban and Vitamin K Antagonists for the Anticoagulation for the Implantation of Vena Cava Filters","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2020-05-08","conditions":"Venous Thromboembolism","enrollment":200},{"nctId":"NCT02744092","phase":"NA","title":"Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer","status":"COMPLETED","sponsor":"Alliance Foundation Trials, LLC.","startDate":"2016-12-13","conditions":"Cancer, Venous Thromboembolism, Deep Vein Thrombosis (DVT)","enrollment":811},{"nctId":"NCT05546957","phase":"NA","title":"Assess Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban in Healthy Adult Participants","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2023-01-05","conditions":"Healthy Volunteer","enrollment":60},{"nctId":"NCT04542408","phase":"PHASE3","title":"Hamburg Edoxaban for Anticoagulation in COVID-19 Study","status":"COMPLETED","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2020-11-12","conditions":"Covid19","enrollment":140},{"nctId":"NCT04002011","phase":"PHASE2","title":"DOAC Versus VKA After Cardiac Surgery","status":"WITHDRAWN","sponsor":"Laval University","startDate":"2022-03-09","conditions":"Anticoagulant-induced Bleeding","enrollment":""},{"nctId":"NCT04569279","phase":"PHASE3","title":"Rivaroxaban vs. Warfarin in CVT Treatment","status":"COMPLETED","sponsor":"Damascus University","startDate":"2017-09-01","conditions":"Cerebral Vein Thrombosis","enrollment":71},{"nctId":"NCT05705076","phase":"NA","title":"Efficacy of Direct Oral Anticoagulants as a Prophylactic Anticoagulation of Catheter Induced Thrombosis","status":"UNKNOWN","sponsor":"Mansoura University","startDate":"2023-01-24","conditions":"Anticoagulants; Increased","enrollment":1100},{"nctId":"NCT01999179","phase":"NA","title":"Post-thrombotic Syndrome & Predictors of Recurrence in Catheter-related Thrombosis","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2014-06","conditions":"Venous Thrombosis, Neoplasms","enrollment":27},{"nctId":"NCT05189002","phase":"PHASE2","title":"A Study to Evaluate Dimolegin in Prevention of Thromboembolic Complications During Knee Replacement","status":"UNKNOWN","sponsor":"PharmaDiall Ltd.","startDate":"2019-05-31","conditions":"Venous Thromboembolism","enrollment":240},{"nctId":"NCT04275778","phase":"PHASE2","title":"HYDROxychloroquine in Syndrome Primary AntiPhospholipid","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-07-09","conditions":"Antiphospholipid Syndrome in Pregnancy, Anticoagulants","enrollment":110},{"nctId":"NCT02329327","phase":"PHASE3","title":"A Study in Participants With Acute Major Bleeding to Evaluate the Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Direct and Indirect Oral Anticoagulants (Extension Study)","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2015-04-10","conditions":"Bleeding","enrollment":479},{"nctId":"NCT05233124","phase":"PHASE2","title":"Antithrombotic Therapy in Acute Coronary Syndromes and Coronary Artery Ectasia","status":"UNKNOWN","sponsor":"Instituto Nacional de Cardiologia Ignacio Chavez","startDate":"2021-09-01","conditions":"Acute Coronary Syndrome, Coronary Artery Ectasia","enrollment":60},{"nctId":"NCT04727437","phase":"PHASE3","title":"STOPping Anticoagulation for Isolated or Incidental Subsegmental Pulmonary Embolism","status":"UNKNOWN","sponsor":"University of Birmingham","startDate":"2021-04-08","conditions":"Subsegmental Pulmonary Embolism Nos","enrollment":1466},{"nctId":"NCT04935515","phase":"NA","title":"C Reactive Protein in Home Quarantined Coronavirus Disease 2019 (COVID -19) Patients.","status":"COMPLETED","sponsor":"Manimarane Arjunan, MD,DM (Cardiology)","startDate":"2021-04-15","conditions":"COVID -19","enrollment":25},{"nctId":"NCT04173429","phase":"PHASE4","title":"Efficacy and Safety of Anticoagulant Therapy in Portal Vein Thrombosis","status":"COMPLETED","sponsor":"Qilu Hospital of Shandong University","startDate":"2017-01-01","conditions":"Liver Cirrhosis, Portal Vein Thrombosis","enrollment":64},{"nctId":"NCT03073850","phase":"PHASE4","title":"Antithrombotic Treatment in Patients With Effectively Maintained Sinus Rhythm After Atrial Fibrillation Ablation","status":"TERMINATED","sponsor":"Korea University Guro Hospital","startDate":"2017-02-23","conditions":"Atrial Fibrillation","enrollment":48},{"nctId":"NCT04192552","phase":"NA","title":"Perioperative Anticoagulant Use for Surgery Evaluation Study Part 2 Pilot","status":"UNKNOWN","sponsor":"McMaster University","startDate":"2020-01-09","conditions":"Atrial Fibrillation","enrollment":201},{"nctId":"NCT01727427","phase":"","title":"Prospective Study on the Treatment of Unsuspected Pulmonary Embolism in Cancer Patients","status":"COMPLETED","sponsor":"G. d'Annunzio University","startDate":"2012-11","conditions":"Unsuspected Pulmonary Embolism","enrollment":695},{"nctId":"NCT02072434","phase":"PHASE3","title":"Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Nonvalvular Atrial Fibrillation (NVAF)","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2014-03-25","conditions":"Atrial Fibrillation","enrollment":2199},{"nctId":"NCT01857622","phase":"PHASE3","title":"Safety and Pharmacokinetics Study of DU-176b Administered to Non-valvular Atrial Fibrillation With Severe Renal Impairment","status":"COMPLETED","sponsor":"Daiichi Sankyo Co., Ltd.","startDate":"2011-11","conditions":"Non-valvular Atrial Fibrillation","enrollment":93},{"nctId":"NCT03804697","phase":"NA","title":"Selective Thromboembolism Prophylaxis After Arthroplasty","status":"COMPLETED","sponsor":"Guangdong Provincial People's Hospital","startDate":"2016-08-01","conditions":"Venous Thrombosis, Deep, Arthroplasty Complications","enrollment":197},{"nctId":"NCT02238444","phase":"PHASE4","title":"Warfarin Prevents Portal Vein Thrombosis in Liver Cirrhotic Patients With Hypersplenism After Laparoscopic Splenectomy","status":"UNKNOWN","sponsor":"Yangzhou University","startDate":"2014-09-01","conditions":"Cirrhosis, Hypertension, Venous Thrombosis","enrollment":60},{"nctId":"NCT00790842","phase":"PHASE1, PHASE2","title":"Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction","status":"TERMINATED","sponsor":"PrECOG, LLC.","startDate":"2009-01-21","conditions":"Multiple Myeloma, Plasma Cell Neoplasm","enrollment":63},{"nctId":"NCT02550717","phase":"","title":"Epidemiological Study on the Safety of Aspirin in The Health Improvement Network (THIN)","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-09-01","conditions":"Secondary Prevention, Stroke, Ischemic Heart Disease","enrollment":398158},{"nctId":"NCT03456648","phase":"PHASE2","title":"Apixaban in End-stage Kidney Disease : A Pharmacokinetics Study","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2016-09-25","conditions":"ESRD, Anticoagulant Toxicity","enrollment":24},{"nctId":"NCT00800137","phase":"PHASE4","title":"Bridge or Continue Coumadin for Device Surgery Randomized Controlled Trial","status":"TERMINATED","sponsor":"Ottawa Heart Institute Research Corporation","startDate":"2008-12","conditions":"Hematoma","enrollment":984},{"nctId":"NCT00700895","phase":"PHASE3","title":"Assessing the Clinical Benefits of a Pharmacogenetics-Guided Dosing Regiment for Calculating Warfarin Maintenance Dose","status":"UNKNOWN","sponsor":"National University Hospital, Singapore","startDate":"2006-08","conditions":"Indications for Warfarin Therapy","enrollment":320},{"nctId":"NCT00641732","phase":"PHASE2","title":"Efficacy and Safety of TAK-442 in Subjects Undergoing Total Knee Replacement","status":"COMPLETED","sponsor":"Takeda","startDate":"2007-10","conditions":"Venous Thromboembolism","enrollment":1045},{"nctId":"NCT00345618","phase":"PHASE3","title":"Clinical Study Assessing Idrabiotaparinux Sodium Injections Once-weekly in Pulmonary Embolism Therapeutic Approach","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-06","conditions":"Embolism, Thrombosis","enrollment":3202},{"nctId":"NCT00902928","phase":"PHASE2, PHASE3","title":"A Study Evaluating Efficacy and Safety of YM150 Compared to Enoxaparin in Subjects Undergoing Hip Replacement Surgery","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2009-04","conditions":"Venous Thromboembolism, Arthroplasty, Replacement, Hip","enrollment":1992},{"nctId":"NCT01727453","phase":"PHASE4","title":"Compare VKA vs LMWH in Patients With Anticoagulation Criteria and Episode of Gastrointestinal Bleeding.","status":"COMPLETED","sponsor":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","startDate":"2011-12","conditions":"Acute Gastrointestinal Bleeding","enrollment":40},{"nctId":"NCT01141153","phase":"PHASE4","title":"Anticoagulation in Stent Intervention","status":"UNKNOWN","sponsor":"Hospital Universitari Vall d'Hebron Research Institute","startDate":"2010-06","conditions":"Atrial Fibrillation, Stroke","enrollment":304},{"nctId":"NCT01758640","phase":"PHASE3","title":"Safety And Efficacy of Low Dose Oral Anticoagulants And Aspirin Therapy","status":"COMPLETED","sponsor":"Yasser Elnahas","startDate":"2010-02","conditions":"Anticoagulation in Pregnancy","enrollment":200},{"nctId":"NCT00917254","phase":"PHASE2, PHASE3","title":"Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement Surgery","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2009-05","conditions":"Venous Thromboembolism","enrollment":369},{"nctId":"NCT00913120","phase":"PHASE2, PHASE3","title":"Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Hip Replacement Surgery","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2009-05","conditions":"Venous Thromboembolism","enrollment":610},{"nctId":"NCT00711308","phase":"PHASE4","title":"Tinzaparin in the Treatment of the Acute Pulmonary Embolism","status":"COMPLETED","sponsor":"Complejo Hospitalario Xeral-Calde","startDate":"2005-04","conditions":"Acute Pulmonary Embolism","enrollment":102},{"nctId":"NCT00689520","phase":"PHASE4","title":"Long-Term Low-Molecular-Weight Heparin Versus Oral Anticoagulants in Deep Venous Thrombosis","status":"COMPLETED","sponsor":"Hospital Universitari de Bellvitge","startDate":"2002-01","conditions":"Venous Thromboembolism","enrollment":241}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Edoxaban of 30mg"],"phase":"marketed","status":"active","brandName":"Low dose oral anticoagulant","genericName":"Low dose oral anticoagulant","companyName":"Korea University Guro Hospital","companyId":"korea-university-guro-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Low-dose oral anticoagulants inhibit blood coagulation factors to reduce thrombus formation while minimizing bleeding risk through reduced dosing. Used for Thromboprophylaxis or stroke prevention (specific indication unclear without additional product details).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}